One of the biggest ethical challenges with drug safety is the need for patients and providers to understand that even after a drug is approved, there is still more to learn about its benefits and potential harms, according to Ruth R. Faden, PhD, MPH, Philip Franklin Wagley Professor of Biomedical Ethics and Director of the Johns Hopkins Berman Institute of Bioethics in Baltimore, MD.